Cerestat NMDA receptor antagonist: CNSI discontinued its Phase III trial after an interim analysis indicated a lack of efficacy (see Noteworthy, BioCentury Part

Cambridge NeuroScience Inc. (CNSI), Cambridge, Mass.
Product: Cerestat NMDA

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE